Author

A. M. Ring

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:protein design· 1 Assay:proteomics· 1

Frequent Co-Authors

A. C. Kruse· 1 shared A. Manglik· 1 shared A. S. Baier· 1 shared A. Swaminathan· 1 shared A. Wang· 1 shared B. K. Hilliard· 1 shared C. B. Wilen· 1 shared C. E. Rosen· 1 shared

Activity by Year

2017-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. C. Kruse

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

REAP: A platform to identify autoantibodies that target the human exoproteome

E. Y. Wang, Y. Dai, C. E. Rosen, M. M. Schmitt, M. X. Dong, E. M. N. Ferre, F. Liu, Y. Yang, J. A. Gonzalez-Hernandez, E. Meffre, M. Hinchcliffe, F. Koumpouras, M. S. Lionakis, A. M. Ring

REAP identifies autoantibodies targeting the human exoproteome by screening patient samples against a yeast-displayed extracellular protein library, revealing known and novel reactivities in autoimmune diseases.

bioRxiv · Feb 11, 2021Immunology

Type I Interferon Limits Viral Dissemination-Driven Clinical Heterogeneity in a Native Murine Betacoronavirus Model of COVID-19

H. Qing, L. Sharma, B. K. Hilliard, X. Peng, A. Swaminathan, J. Tian, K. Israni-Winger, C. Zhang, D. Leao, S. Ryu, V. Habet, L. Wang, X. Tian, S. Ishibe, L. H. Young, , A. Wang

This study establishes a murine model of COVID-19 using MHV-A59 and shows that type-I interferons limit viral dissemination, reducing lethality and recapitulating key clinical features.

bioRxiv · Sep 11, 2020 · PreprintImmunology

Platform for rapid nanobody discovery in vitro

C. McMahon, A. S. Baier, S. Zheng, R. Pascolutti, J. X. Ong, S. C. Erlandson, D. Hilger, A. M. Ring, A. Manglik, A. C. Kruse

This paper presents an in vitro platform for rapid nanobody discovery using yeast surface display, demonstrating its application to various antigens including lipid flippase and G protein-coupled receptors.

bioRxiv · Jun 16, 2017Biochemistry